Prescription Drug Education and Explainers

This project aims to provide timely, nonpartisan analysis of federal and state drug policy proposals as
well as educational explainers to ensure policymakers can engage in meaningful dialogue on prescription drug reform. Each analysis will highlight Fund-supported research, frame the issue the policy is attempting to address, consider other relevant policy options with a focus on health equity, and interpret policy nuances for a wider audience. Final decisions on topics will be decided jointly between the grantee and Fund staff, but may include topics such as product-hopping, generic and biosimilar competition, pharmaceutical benefit managers, spread pricing, the accelerated approval pathway, and the 340B program.